TrialsgrambetaRCTs are beautiful

MERINO

2018

Piperacillin-Tazobactam vs Meropenem for ESBL Bacteraemia

In 391 patients with ceftriaxone-non-susceptible E. coli or K. pneumoniae bacteraemia, piperacillin-tazobactam increased 30-day mortality compared with meropenem.

Result

30-day all-cause mortality
Absolute difference
8.6 points
Effect estimate

risk difference8.6P = 0.90

The absolute difference is derived from the event rates.

Also reported: For noninferiority: noninferiority not met.

Original publication
Subtopic
ESBL bacteraemia
Design
Open-label non-inferiority RCT
Relevance
Important: one of several pillars.
Source
Harris PNA, et al. JAMA. 2018;320(10):984-994.doi 10.1001/jama.2018.12163

Discussion & critique

Definitive evidence to use carbapenems for ESBL bloodstream and intra-abdominal infection: piperacillin-tazobactam is not equivalent.

Discussed in podcasts